Chronic Wounds - Pipeline Insight, 2025

This “Chronic Wounds - Pipeline Insight, 2025” report provides comprehensive insights about 3+ companies and 3+ pipeline drugs in Chronic Wounds pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.

Geography Covered

Chronic Wounds: Understanding

Chronic Wounds: Overview

Chronic Wounds is wound is one that fails to progress through a normal, orderly, and timely sequence of repair, or in which the repair process fails to restore anatomic and functional integrity after three months. Chronic wounds are often termed ulcers and can be defined as wounds with a full thickness in depth and a slow healing tendency. Examples of chronic wounds include non-healing or infected surgical or traumatic wounds, venous ulcers, pressure ulcers, diabetic foot ulcers, and ischemic ulcers. Chronic Wounds are mainly classified as vascular ulcers (e.g., venous and arterial ulcers), diabetic ulcers, and pressure ulcers.

Chronic wounds are typically identified by a raised, hyperproliferative, yet non-advancing wound margin. The area around the wound will be inflamed and this inflammation may affect healing negatively. Common sign and symptoms include fever, redness around the wound and warm to touch, milky, yellow, green, or brown pus in the wound, bleeding, swelling, or pain in the affected area, trouble moving the affected area, wound has become larger or deeper, and dark or black skin around the wound.

Some of the common causes for chronic wounds include: diabetes, vascular diseases like peripheral artery disease, limited mobility, repeated trauma to wound site, infection-causing bacteria like Staphylococcus aureus and edema. Some of the causalities in creation of chronic wounds are, but not limited to: poor circulation, unusual local pressure to the wound site, existence of neuropathy which causes loss of protective sensation, risk of infection, unresolved inflammation, and other severe impaired healing processes such as lack of angiogenesis, epithelial migration, and cell proliferation. The impact of these problems on chronic wounds is heightened by having complex diseases out of control, for example, by glucose accumulation in the wound site.

Assessment of wounds should begin with a thorough physical examination. A more focused examination of the wound itself can then help guide treatment. The wound location, size, and depth; presence of drainage; and tissue type should be documented. Based on the location and appearance, most chronic wounds can be categorized by etiology, which allows for adequate workup and treatment recommendations. Local treatment for Chronic wound is directed toward reducing pain and itching, minimizing infection and bleeding from the wound. Other treatment may depend on an affected individual’s specific symptoms and thorough assessment with medical and nutritional optimization, debridement (including surgery), offloading (or compression), management of ischemia, management of infection, and appropriate wound bed preparation. In addition, the rational use of advanced wound care therapies is encouraged. Chronic wounds related to malignancy require appropriate treatment of the malignancy, but in some cases, palliation may be all that can be offered.

"Chronic Wounds- Pipeline Insight, 2025" report outlays comprehensive insights of present scenario and growth prospects across the indication. A detailed picture of the Chronic Wounds pipeline landscape is provided which includes the disease overview and Chronic Wounds treatment guidelines. The assessment part of the report embraces, in depth Chronic Wounds commercial assessment and clinical assessment of the pipeline products under development. In the report, detailed description of the drug is given which includes mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, Chronic Wounds collaborations, licensing, mergers and acquisition, funding, designations and other product related details.

Report Highlights

The companies and academics are working to assess challenges and seek opportunities that could influence Chronic Wounds R&D. The therapies under development are focused on novel approaches to treat/improve Chronic Wounds.

Chronic Wounds Emerging Drugs Chapters

This segment of the Chronic Wounds report encloses its detailed analysis of various drugs in different stages of clinical development, including Phase III, II, I, Preclinical and Discovery. It also helps to understand clinical trial details, expressive pharmacological action, agreements and collaborations, and the latest news and press releases.

Chronic Wounds Emerging Drugs

SkinTE: PolarityTE

SkinTE is a human cellular and tissue-based product derived from a patient's own skin intended for the repair, reconstruction, and replacement of skin tissue. SkinTE is intended to be used by physicians or other appropriate healthcare providers for homologous uses of skin tissues/integument. Patients who have suffered from an event, disease, and process or acquired deficit that results in the functional loss or void of skin/integument systems can receive SkinTE as an adjunct and/or in place of split-thickness skin grafting, full-thickness grafting, temporizing skin coverage and/or skin substitute products. Currently, the drug is in Phase III stage of its clinical trial for the treatment of chronic wounds.

Chronic Wounds: Therapeutic Assessment

This segment of the report provides insights about the different Chronic Wounds drugs segregated based on following parameters that define the scope of the report, such as:

Major Players in Chronic Wounds

• There are approx. 3+ key companies which are developing the therapies for Chronic Wounds. The companies which have their Chronic Wounds drug candidates in the most advanced stage, i.e. Phase III include, PolarityTE.

Phases

The report covers around 3+ products under different phases of clinical development like

• Late stage products (Phase III)
• Mid-stage products (Phase II)
• Early-stage product (Phase I) along with the details of
• Pre-clinical and Discovery stage candidates
• Discontinued & Inactive candidates

Route of Administration

Chronic Wounds pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as

• Oral
• Intravenous
• Subcutaneous
• Parenteral
• Topical

Molecule Type

Products have been categorized under various Molecule types such as

• Recombinant fusion proteins
• Small molecule
• Monoclonal antibody
• Peptide
• Polymer
• Gene therapy

Product Type

Drugs have been categorized under various product types like Mono, Combination and Mono/Combination.

Chronic Wounds: Pipeline Development Activities

The report provides insights into different therapeutic candidates in Phase III, II, I, preclinical and discovery stage. It also analyses Chronic Wounds therapeutic drugs key players involved in developing key drugs.

Pipeline Development Activities

The report covers the detailed information of collaborations, acquisition and merger, licensing along with a thorough therapeutic assessment of emerging Chronic Wounds drugs.

Chronic Wounds Report Insights

• Chronic Wounds Pipeline Analysis
• Therapeutic Assessment
• Unmet Needs
• Impact of Drugs

Chronic Wounds Report Assessment

• Pipeline Product Profiles
• Therapeutic Assessment
• Pipeline Assessment
• Inactive drugs assessment
• Unmet Needs

Key Questions

Current Treatment Scenario and Emerging Therapies:

• How many companies are developing Chronic Wounds drugs?
• How many Chronic Wounds drugs are developed by each company?
• How many emerging drugs are in mid-stage, and late-stage of development for the treatment of Chronic Wounds?
• What are the key collaborations (Industry-Industry, Industry-Academia), Mergers and acquisitions, licensing activities related to the Chronic Wounds therapeutics?
• What are the recent trends, drug types and novel technologies developed to overcome the limitation of existing therapies?
• What are the clinical studies going on for Chronic Wounds and their status?
• What are the key designations that have been granted to the emerging drugs?

Key Players

• PolarityTE
• Aurealis Therapeutics
• Akribes Biomedical

Key Products

• SkinTE
• AUP1602-C
• AKR 201

This product will be delivered within 2 business days.